Redwood Pharma AB (REDW.ST)

0.2005 -0.0165 (-7.60%) At close: 05:13PM CET

Redwood Pharma AB

Ringvagen 100E
9th Floor
Stockholm 118 60
Sweden

https://www.redwoodpharma.se

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 2

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Martin Vidaeus M.B.A., MBA	Founder, CEO & Director	N/A	N/A	1966
Mr. Hans Ageland MSEng	Founder & COO	N/A	N/A	1961
Mr. Peter Rooslien B.A., BA	Chief Financial Officer	N/A	N/A	1956
Mr. Ulf Bjorklund M.Sc.	Chief Medical Officer	N/A	N/A	1956

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Redwood Pharma AB engages in the development of ophthalmic pharmaceutical therapies for unmet market needs. The company's lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women. It uses IntelliGel, a supramolecular smart drug delivery system for development of topical formulation for ophthalmic uses, as well as for administration to the front of the eye. Redwood Pharma AB is based in Stockholm, Sweden.

Corporate Governance

Redwood Pharma AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.